Ondokuz Mayıs University Faculty of Medicine, Department of Ophthalmology, Samsun, Turkey
Turk J Ophthalmol. 2020 Mar 5;50(1):50-52. doi: 10.4274/tjo.galenos.2019.79026.
Vemurafenib is a potent inhibitor of genetically activated BRAF, which is responsible for tumoral proliferation in cutaneous melanoma. A 56-year-old man receiving vemurafenib therapy presented with uveitis. Over the course of the disease, he developed bilateral, granulomatous uveitis with multiple peripheral chorioretinal lesions. Serum angiotensin-converting enzyme levels increased. The patient was diagnosed with probable ocular sarcoidosis related to vemurafenib and was treated with an intravitreal dexamethasone implant. This case is the first report that shows the clinical and angiographic features of a patient with vemurafenib-related sarcoid-like granulomatous uveitis.
维莫非尼是一种有效的基因激活 BRAF 抑制剂，该基因负责皮肤黑色素瘤的肿瘤增殖。一位正在接受维莫非尼治疗的 56 岁男性出现了葡萄膜炎。在疾病过程中，他出现了双侧肉芽肿性葡萄膜炎，并伴有多个周边脉络膜视网膜病变。血清血管紧张素转换酶水平升高。患者被诊断为可能与维莫非尼相关的眼结节病，并接受了玻璃体内地塞米松植入物治疗。该病例是首例报告，显示了与维莫非尼相关的类肉瘤样肉芽肿性葡萄膜炎患者的临床和血管造影特征。
